NEW ZEALAND DATA SHEET

1 NAME OF THE MEDICINE
Arrow-Bendrofluazide 2.5, 2.5 mg, tablets
Arrow-Bendrofluazide 5, 5 mg, tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 2.5 mg or 5 mg of bendroflumethiazide (also known as bendrofluazide).
Excipient with known effect: lactose

For the full list of excipients, see section 6.1 List of excipients.

3 PHARMACEUTICAL FORM
Tablets 2.5 mg: White to almost white, circular, biconvex, uncoated tablets.
Tablets 5 mg: White to almost white, circular, flat, bevelled edged uncoated tablets with ‘5’ embossed on one side.
Do not halve the tablets. Dose equivalence when the tablet is divided has not been established.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications
Bendroflumethiazide is indicated in the treatment of oedema associated with conditions such as: congestive heart failure, nephrotic syndrome and cirrhosis of the liver.

Bendroflumethiazide is indicated in the treatment of essential hypertension where it may be used as the sole antihypertensive agent, or as an adjunct to other medicines whose action it potentiates.

4.2 Dose and method of administration

Adults
When bendroflumethiazide is added to other antihypertensive agents, the dosage of the latter can usually be reduced gradually as bendroflumethiazide takes effect.

Oedema
Initially 5 to 10 mg once daily or on alternate days.
Maintenance: 2.5 to 10 mg two or three times weekly.

5 mg given orally once daily in the morning usually produces the desired effect without diuresis interfering with sleep, but this dose can be increased to 10 mg if required. During the first few days of treatment there is usually a large increase in urinary volume, which diminishes as treatment continues.

Essential hypertension
2.5 mg to 10 mg once daily, alone or in conjunction with other antihypertensive agents.

Doses higher than 2.5 mg per day (for hypertension) are rarely necessary.

Elderly
The dosage of thiazide diuretics may need to be reduced in the elderly, particularly when renal function is impaired, because of the possibility of electrolyte imbalance.

Children
For children up to 12 years of age, 50-100 mcg/kg bodyweight daily.

4.3 Contraindications
• Hypersensitivity to bendroflumethiazide or other sulphonamide-like medicines, thiazide diuretics or to any of the excipients listed in section 6.1 (List of excipients)
• Severe renal or hepatic insufficiency
• Hypercalcaemia; refractory hypokalaemia; hyponatraemia; symptomatic hyperuricaemia
• Addison's disease
• Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine
• Diabetic keto-acidosis
• Treatment with lithium carbonate

4.4 Special warnings and precautions for use

Bendroflumethiazide may raise serum uric acid levels with consequent exacerbation of gout in susceptible patients.

Thiazide diuretics should be used with caution in patients with mild or moderate renal or hepatic dysfunction. Renal function should be monitored during bendroflumethiazide therapy. Thiazides can cause electrolyte imbalance which is more severe in patients with hepatic and renal impairment and in those receiving higher or prolonged doses.

Elderly patients and those on intensive or long term treatment need regular blood tests to monitor serum electrolytes (especially potassium). Hypokalaemia should be corrected by adding potassium supplements to the regimen and may be required in the following cases:

- if the patient is vomiting, has diarrhoea or is suffering from an acute febrile or chronic illness (especially cirrhosis of the liver or heart failure).
- to prevent hypokalaemia, possible arrhythmias and other ECG changes in patients receiving digitalis especially if diuretic treatment is prolonged.
- in patients at risk of myocardial infarction.
- in patients admitted for cardiac surgery.
- in patients receiving concurrent therapy with carbenoxolone or corticosteroids.

Potassium depletion may cause polyuria, malaise, muscle weakness or cramp, decreased tendon reflexes, anorexia, dizziness, nausea or vomiting. Also, sensitivity to digitalis may increase and signs of overdosage appear. Prolonged potassium deficiency may induce chronic pyelonephritis.

Potassium supplements must not be given in renal insufficiency complicated by hypokalaemia. In renal insufficiency, renal function should be monitored. In prolonged therapy it is necessary to test for glycosuria and investigate polyuria. The possibility of magnesium depletion should be considered.

In cirrhosis of the liver, thiazides may precipitate hepatic encephalopathy. The risk of hypomagnesaemia is increased in alchoholic cirrhosis.

Thiazides may decrease urinary calcium excretion and may cause intermittent and slight elevation of serum calcium. Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.

Systemic lupus erythematosus (SLE) may be exacerbated by bendroflumethiazide.

Diabetes mellitus may be aggravated by bendroflumethiazide and cause symptoms in patients with latent disease. Bendroflumethiazide may impair control of diabetes in patients receiving sulphonylureas.

Caution is required when treating patients with porphyria.

Thiazides may cause or aggravate hyperlipidaemia.

Patients taking pimozide or thioridazine see section 4.5 Interaction with other medicinal products and other forms of interaction.
Choroidal effusion, acute myopia and secondary angle-closure glaucoma

Sulfonamide or sulfonamide derivative drugs can cause an idiosyncratic reaction resulting in choroidal effusion with visual field defect, transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.

Elderly

The elderly are sensitive to the effects of thiazides on blood pressure and electrolytes. Administration of supplementary potassium is particularly important in the elderly. Patients with prostatic hypertrophy may develop acute urinary retention.

4.5 Interaction with other medicines and other forms of interaction

*Allopurinol:* Bendroflumethiazide may antagonise the action of allopurinol by causing retention of urate in the kidney. Caution is advised when using this combination.

*Anion exchange resins:* Colestyramine and colestipol reduce absorption of bendroflumethiazide. This can be prevented by leaving an interval of two hours between doses of bendroflumethiazide and the anion exchange resin. *Antiarhythmics:* The cardiotoxicity of disopyramide, amiodarone, flecainide and quinidine is increased if hypokalaemia occurs following the administration of bendroflumethiazide. The actions of lidocaine and mexiletine are antagonised by hypokalaemia.

*Antidepressants:* There is an increased risk of postural hypotension if bendroflumethiazide is given with tricyclic antidepressants. There may also be a risk of hypokalaemia if thiazides are given with reboxetine. Concomitant use with MAOIs may result in an enhanced hypotensive effect.

*Antidiabetics:* Bendroflumethiazide antagonises the hypoglycaemic effects of sulfonylureas, with a potential loss of diabetic control.

*Antiepileptics:* There is an increased risk of hyponatraemia when bendroflumethiazide and carbamazepine are taken concurrently.

*Antifungals:* The risk of hypokalaemia is increased when amphotericin and bendroflumethiazide are taken concurrently.

*Antihypertensives:* Bendroflumethiazide may enhance the antihypertensive effect of ACE inhibitors and angiotensin-II antagonists. There is an increased risk of first dose hypotension if prazosin is given to a patient taking bendroflumethiazide.

*Antipsychotics:* Hypokalaemia increases the risk of ventricular arrhythmias with pimozide or thioridazine so concomitant use should be avoided.

*Calcium salts:* Bendroflumethiazide reduces urinary excretion of calcium so there is an increase risk of hypercalcaemia when calcium salts are taken concurrently. Serum calcium levels should be monitored to ensure that they do not become excessive.

*Calcium channel blockers and peripheral vasodilators:* The hypotensive effect of calcium channel blockers and moxisylyte may be enhanced when co-administered with bendroflumethiazide.

*Corticosteroids:* Corticosteroids may exacerbate hypokalaemia associated with bendroflumethiazide and its diuretic activity may be antagonised.

*Cytotoxics:* Concomitant use with cisplatin can lead to an increased risk of nephrotoxicity and ototoxicity.

*Digoxin:* The hypokalaemic effect of bendroflumethiazide may enhance sensitivity to digoxin when taken concurrently. Patients should be monitored for signs of digoxin intoxication, especially arrhythmias. The dose of digoxin should be reduced and potassium supplements given, should digoxin toxicity develop.
**Hormone antagonists:** There is an increased risk of hyponatraemia when bendroflumethiazide is used concomitantly with aminoglutethamide. Bendroflumethiazide can cause an increased risk of hypercalcaemia when co-administered with toremifene.

**Lithium:** Bendroflumethiazide inhibits the tubular elimination of lithium, resulting in an elevated plasma lithium concentration and risk of toxicity. Plasma lithium concentrations must be monitored when these drugs are given concurrently.

**Muscle relaxants:** The hypotensive activity of bendroflumethiazide may be increased by baclofen and tizanidine. Bendroflumethiazide may enhance the neuromuscular blocking activity of non-depolarising muscle relaxants, such as tubocurarine, gallamine, alcuronium and pancuronium.

**NSAIDs:** Bendroflumethiazide may enhance the nephrotoxicity of NSAIDs. Indometacin and ketorolac antagonise the diuretic effect of bendroflumethiazide, this occurs to a lesser extent with ibuprofen, piroxicam and naproxen. The effects of concurrent use should be monitored and the dose of bendroflumethiazide modified if necessary.

**Oestrogens and progestogens:** Oestrogens and combined oral contraceptives antagonise the diuretic effect of bendroflumethiazide.

**Sympathomimetics:** Sympathomimetics can cause hypokalaemia. The risk of serious heart arrhythmias in asthmatic patients may be increased if bendroflumethiazide is added to their medication.

**Theophylline:** Concomitant administration of theophylline and bendroflumethiazide increases the risk of hypokalaemia.

**Ulcer healing drugs:** There is an increased risk of hypokalaemia and a decrease in diuretic activity when carbenoxolone and bendroflumethiazide are taken together. Patients should be monitored and given potassium supplements when required.

**Vitamins:** The risk of hypercalcaemia is increased if bendroflumethiazide is given with vitamin D.

### 4.6 Fertility, pregnancy and lactation

**Pregnancy**

Bendroflumethiazide is best avoided for the management of oedema of pregnancy or hypertension in pregnancy as it crosses the placenta and its use may be associated with hypokalaemia, increased blood viscosity and reduced placental perfusion. There is inadequate evidence of safety in human pregnancy. There are rare reports of foetal and neonatal bone marrow depression, thrombocytopenia, electrolyte imbalance, hypoglycaemia and jaundice.

Expectant mothers who receive thiazide diuretics may be at increased risk from acute haemorrhagic pancreatitis.

In parturition, thiazides may cause uterine inertia and delay the onset of labour.

Thiazides are only indicated in pregnancy if oedema complicates a pathological lesion and, even then, after assessing risk versus benefit including the undesirability of administering medicines in the first trimester.

**Breastfeeding**

Bendroflumethiazide suppresses lactation and, although the amounts passing into breast milk are small, it should be avoided in breast feeding mothers.

**Fertility**

No information available.

### 4.7 Effects on ability to drive and use machines

As bendroflumethiazide can cause dizziness, patients should make sure they are not affected before driving or operating machinery.
4.8 Undesirable effects
The frequencies of adverse events are ranked according to the following: very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$), very rare ($< 1/10,000$), not known (cannot be estimated from the available data).

Blood and lymphatic system disorders
Not known: Blood dyscrasia including agranulocytosis, aplastic anaemia, thrombocytopenia and leucopenia

Metabolism and nutrition disorders
Not known: Hypokalaemia, hypomangnesiaemia, hyponatraemia, hypercalcaemia, hypochloraemic alkalosis. Hypokalaemia may result in polyuria, malaise, muscle weakness or cramp, dizziness, nausea, anorexia or vomiting

Nervous system disorders
Not known: Dizziness

Vascular disorders
Not known: Postural hypotension

Respiratory, thoracic and mediastinal disorders
Not known: Pneumonitis, pulmonary oedema

Gastrointestinal disorders
Not known: Nausea, vomiting, diarrhoea, constipation, gastric irritation, pancreatitis have all been reported

Hepatobiliary disorders
Not known: Intrahepatic cholestasis

Skin and subcutaneous tissue disorders
Not known: Rashes (including exfoliative dermatitis), photosensitivity

Reproductive system and breast disorders
Not known: Impotence (reversible on discontinuing the drug)

Investigations
Bendroflumethiazide may lower carbohydrate tolerance and the insulin dosage of some diabetic patients may require adjustment. Care is required when bendroflumethiazide is administered to patients with a known predisposition to diabetes.

Bendroflumethiazide may raise serum uric acid levels and exacerbate gout in susceptible individuals.

Plasma lipids may be altered in patients taking bendroflumethiazide.

Description of selected adverse reactions
Cases of choroidal effusion with visual field defect have been reported after the use of thiazide and thiazide-like diuretics.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions https://nzphvc.otago.ac.nz/reporting/.

4.9 Overdose
Symptoms
Nausea, vomiting, diarrhoea, dehydration, dizziness, weakness, muscle cramps, diuresis, increased frequency of micturition with polyuria and thirst. Extreme cases may show depletion of intravascular
volume, hypotension and peripheral circulatory failure. CNS depression (eg. drowsiness, lethargy and coma) may occur without cardiovascular or respiratory depression. Hypokalaemia and mild hypoglycaemia are likely to be present if diuresis is profound.

**Treatment**

Activated charcoal may help reduce absorption of substantial amounts if given within one hour of ingestion. Treatment should be symptomatic and directed at fluid and electrolyte replacement which should be monitored together with the blood pressure and renal function. Hyponatraemia should be treated with water deprivation rather than the administration of sodium chloride. Cathartics should be avoided.

**5 PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Thiazide diuretics, ATC code: C03AA01

**Mechanism of action**

Bendroflumethiazide inhibits the renal tubular absorption of salt and water. Sodium and chloride ions are excreted in equivalent proportions, and there is little or no disturbance of the acid/base equilibrium. There is no important effect upon carbonic anhydrase. Bendroflumethiazide initiates diuresis in about 2 hours and maintains a steady diuresis lasting for about 12 hours.

The mechanism whereby the thiazides exert their antihypertensive effect has not been clearly established. In non-oedematous patients there may be little noticeable diuretic effect.

**5.2 Pharmacokinetic properties**

The following data apply to Bendroflumethiazide tablets.

Since bendroflumethiazide is completely absorbed from the gastrointestinal tract and only about 30% is excreted unchanged in the urine, the majority of an oral dose being eliminated by non-renal mechanisms, it has been inferred that bendroflumethiazide is extensively metabolised.

It has been suggested that metabolites, some of which may be active, accumulate during chronic treatment and compete with bendroflumethiazide for pathways of tubular secretion. Bendroflumethiazide is estimated to have a plasma half-life of about 3 or 4 hours, its biological half-life being much longer. It is 94% bound to human serum albumin in vitro. The time to reach peak concentration is 2 to 2.5 hours.

**6 PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

Lactose, pregelatinised starch, purified talc and stearic acid.

**6.2 Incompatibilities**

Not applicable.

**6.3 Shelf life**

24 months

**6.4 Special precautions for storage**

Store below 25°C. Protect from heat and light.

Store in the original package.

**6.5 Nature and contents of container**

Blister packs containing 14 or 28 tablets.

HDPE containers containing 500 or 1000 tablets.

Not all pack sizes or pack types may be marketed.
6.6 **Special precautions for disposal**
Any unused medicine or waste material should be disposed of in accordance with local requirements.

7 **MEDICINE SCHEDULE**
Prescription Medicine

8 **SPONSOR**
Teva Pharma (New Zealand) Limited
PO Box 128 244
Remuera
Auckland 1541
Telephone: 0800 800 097

9 **DATE OF FIRST APPROVAL**
10 December 2009

10 **DATE OF REVISION OF THE TEXT**
20 September 2021

Summary table of changes

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.2</td>
<td>Revised dosage information for hypertension and oedema indications, along with addition of dosage instructions for elderly patients, as requested by Medsafe.</td>
</tr>
<tr>
<td>4.3, 4.4, 4.6</td>
<td>Updated to fully align with Teva Company Core Safety Information (CCSI).</td>
</tr>
</tbody>
</table>